Discussion stirs around Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) this week; here is what analysts are saying.

May 26, 2018 - By Rodney Autry

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) LogoInvestors sentiment decreased to 1.19 in Q4 2017. Its down 1.02, from 2.21 in 2017Q3. It worsened, as 11 investors sold Tetraphase Pharmaceuticals, Inc. shares while 25 reduced holdings. 16 funds opened positions while 27 raised stakes. 29.51 million shares or 0.43% more from 29.38 million shares in 2017Q3 were reported.
Moreover, Rhumbline Advisers has 0% invested in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) for 54,187 shares. Strs Ohio stated it has 83,800 shares. Goldman Sachs Group owns 72,524 shares. Jacobs Levy Equity Mgmt Inc owns 141,200 shares or 0.02% of their US portfolio. Numeric Ltd Co holds 1.99 million shares or 0.09% of its portfolio. Axa, a France-based fund reported 216,337 shares. 9,786 are held by Parallax Volatility Advisers Limited Partnership. Macquarie Gru accumulated 5,000 shares or 0% of the stock. Federated Pa holds 0% or 149,055 shares. Vanguard Gru has invested 0% in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH). State Street Corp has invested 0% in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH). Manchester Cap Ltd reported 14,984 shares. Weiss Asset Mngmt L P stated it has 0.01% in Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH). Susquehanna Group Llp owns 18,626 shares. Loring Wolcott & Coolidge Fiduciary Advisors Limited Liability Partnership Ma stated it has 3,600 shares or 0% of all its holdings.

Since January 9, 2018, it had 0 insider purchases, and 2 insider sales for $98,932 activity.

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Ratings Coverage

Among 6 analysts covering Tetraphase Pharmaceutical (NASDAQ:TTPH), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Tetraphase Pharmaceutical had 10 analyst reports since February 12, 2018 according to SRatingsIntel. The stock has “Buy” rating by Gabelli on Thursday, March 29. The firm has “Market Perform” rating by BMO Capital Markets given on Wednesday, February 14. The rating was maintained by FBR Capital on Wednesday, February 21 with “Buy”. The firm has “Buy” rating given on Monday, February 12 by FBR Capital. The firm has “Market Perform” rating by BMO Capital Markets given on Thursday, March 8. The firm has “Buy” rating by SunTrust given on Wednesday, February 14. The stock has “Buy” rating by FBR Capital on Wednesday, March 7. The stock of Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) has “Buy” rating given on Tuesday, February 27 by FBR Capital. Below is a list of Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) latest ratings and price target changes.

29/03/2018 Broker: Gabelli Old Rating: Hold New Rating: Buy Upgrade
08/03/2018 Broker: BMO Capital Markets Old Rating: Market Perform New Rating: Market Perform Old Target: $2.75 New Target: $3 Maintain
07/03/2018 Broker: FBR Capital Rating: Buy Maintain
27/02/2018 Broker: FBR Capital Rating: Buy New Target: $6.0 Maintain
23/02/2018 Broker: WBB Securities Rating: Speculative Buy New Target: $6 Initiates Coverage On
21/02/2018 Broker: FBR Capital Rating: Buy Maintain
14/02/2018 Broker: SunTrust Rating: Buy New Target: $10.0 Maintain
14/02/2018 Broker: BMO Capital Markets Old Rating: Outperform New Rating: Market Perform Old Target: $24 Downgrade
12/02/2018 Broker: FBR Capital Rating: Buy New Target: $11.0 Initiate
12/02/2018 Broker: B. Riley & Co Rating: Buy New Target: $11 Initiates Coverage On

The stock increased 1.91% or $0.07 during the last trading session, reaching $3.73. About 234,895 shares traded. Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) has declined 65.91% since May 26, 2017 and is downtrending. It has underperformed by 77.46% the S&P500.

Tetraphase Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company has market cap of $192.58 million. The Company’s lead product candidate is eravacycline, an intravenous and oral antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections. It currently has negative earnings. The firm has completed a Phase III clinical trial of eravacycline with intravenous administration for the treatment of complicated intra-abdominal infections; and initiated a Phase III clinical trial of eravacycline for the treatment of complicated urinary tract infections with intravenous-to- oral transition therapy.

More recent Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) news were published by: Nasdaq.com which released: “Tetraphase Pharmaceuticals to Present Eravacycline and TP-6076 Data at ASM Microbe 2018” on May 21, 2018. Also Seekingalpha.com published the news titled: “Tetraphase Pharmaceuticals, My Favorite 2H 2018 Biotech” on May 23, 2018. Seekingalpha.com‘s news article titled: “Achaogen: Buy Before The June 25 PDUFA Date” with publication date: May 24, 2018 was also an interesting one.

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.